TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34407654

Group type: EXPERIMENTAL
Intervention: Erenumab 70 and 140 mg
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study: 32349746

Group type: EXPERIMENTAL
Intervention: Decision aid with information plus an implicit VCM
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Decision aid with information plus an explicit VCM
Number of subjects: 276

Group type: COMPARATOR
Intervention: Decision aid with information only (control)
Number of subjects: 276
Study: 33310265

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Control (CN)
Number of subjects: 86
Study: 32035553

Group type: EXPERIMENTAL
Intervention: Functional brace
Number of subjects: 540

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 540
Study: 35366822

Group type: EXPERIMENTAL
Intervention: Craniocervical muscle‐strengthening exercise (CMSE) for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham ultrasound treatment for 8 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Craniocervical muscle‐strengthening exercise (CMSE)
Number of subjects: 42
Study: 33753537

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs) with target INR of 2-3
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and vitamin K2
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pooled rivaroxaban groups
Number of subjects: 132
Study: 33203477

Group type: EXPERIMENTAL
Intervention: Biannual community-wide treatment (CWT)
Number of subjects: 167500

Group type: COMPARATOR
Intervention: Annual school-based treatment (SBT)
Number of subjects: 167500

Group type: COMPARATOR
Intervention: Annual CWT
Number of subjects: 167500

Group type: EXPERIMENTAL
Intervention: Biannual CWT
Number of subjects: 167500
Study: 35020706

Group type: EXPERIMENTAL
Intervention: mHealth intervention using MyFitnessPal app, smart scale, and text messages
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 70
Study: 32694382

Group type: EXPERIMENTAL
Intervention: Machine learning analysis of pain parameters
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Cluster assignment
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Decision trees trained with demographic and pain-related variables
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Sleep problems
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Parameters including fear of pain, self-rated poor health, and systolic blood pressure
Number of subjects: 320
Study: 36111922

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo TEAS (no electrical output)
Number of subjects: 60
Study: 34034753

Group type: EXPERIMENTAL
Intervention: MPK C-Leg + 1M10 foot
Number of subjects: 10

Group type: COMPARATOR
Intervention: NMPK with standardized 1M10 foot
Number of subjects: 10
Study: 35640787

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 32605910

Group type: EXPERIMENTAL
Intervention: Eryaspase
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: ctDNA positive at baseline
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Early change in ctDNA levels
Number of subjects: 113
Study: 36459265

Group type: EXPERIMENTAL
Intervention: Primary ureteroscopy (URS) without pre-stenting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Deferred ureteroscopy (URS) after ureteric stenting
Number of subjects: 120
Study: 33279558

Group type: EXPERIMENTAL
Intervention: Phosphate binder prescriptions and dietary recommendations to achieve 'Hi' serum phosphate target (≥6.5 mg/dl)
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Phosphate binder prescriptions and dietary recommendations to achieve 'Lo' serum phosphate target (<5.5 mg/dl)
Number of subjects: 4400
Study: 33983524

Group type: EXPERIMENTAL
Intervention: Worksite self-management program (Manage at Work)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 119
Study: 34794388

Group type: EXPERIMENTAL
Intervention: iGuide intervention (includes video vignettes and a live webinar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGuide intervention (includes electronic health records-based communication and case-based webinars)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGuide intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 0
Study: 33579326

Group type: EXPERIMENTAL
Intervention: Serious game training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Machine learning controlled prosthesis
Number of subjects: 8
Study: 32753845

Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg (test formulation)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Glimepiride 1 mg (reference formulation)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both formulations of glimepiride
Number of subjects: 72
Study: 35144658

Group type: EXPERIMENTAL
Intervention: Wearable activity device and personal consultations (subgroup A)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Wearable activity device (subgroup B)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No support (subgroup C)
Number of subjects: 129
Study: 33389265

Group type: EXPERIMENTAL
Intervention: 0.3% humate (H)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 0.3% probiotic (P)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 0.15% humate + 0.15% probiotic (HP)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 192
Study: 35373894

Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Predictive Low-Glucose Management (PLGM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall HbA1c
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Diabetes burden and worries and fear of hypoglycaemia
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Safety events
Number of subjects: 38
Study: 33748923

Group type: EXPERIMENTAL
Intervention: Bio-Oss collagen
Number of subjects: 40

Group type: COMPARATOR
Intervention: No grafting material
Number of subjects: 40
Study: 32727231

Group type: COMPARATOR
Intervention: Iodine-alcohol
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol and iodine combined
Number of subjects: 2013
Study: 32202698

Group type: EXPERIMENTAL
Intervention: Randomized spacer region in the translation initiation site; specific details on dosage and duration not available.
Number of subjects: 0
Study: 35197416

Group type: EXPERIMENTAL
Intervention: Immediate loading group A (n=81)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional loading group B (n=77)
Number of subjects: 158
Study: 32413693

Group type: EXPERIMENTAL
Intervention: Abnormal P-wave axis (PWA)
Number of subjects: 8899

Group type: EXPERIMENTAL
Intervention: Abnormal P-wave axis (PWA) after multivariable adjustment
Number of subjects: 8899
Study: 35156782

Group type: EXPERIMENTAL
Intervention: Emotional dysregulation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Worry trait
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Avoidance of internal experiences
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-compassion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mindful state
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-compassion as a mediator
Number of subjects: 51
Study: 32586693

Group type: EXPERIMENTAL
Intervention: The Senior Connection (TSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 0
Study: 36088952

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin-clavulanic acid (75 mg/kg amoxicillin + 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Intravenous antibiotics (according to local protocol, for 7 days)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin-clavulanic acid
Number of subjects: 510

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 510
Study: 33415863

Group type: EXPERIMENTAL
Intervention: Long snake moxibustion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ashi-point moxibustion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 35641143

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the dorsal premotor cortex during ischemic nerve block (INB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TMS over the parietal area during ischemic nerve block (INB)
Number of subjects: 0
Study: 33704378

Group type: EXPERIMENTAL
Intervention: 24 Gy SDRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5 × 9 Gy SBRT
Number of subjects: 30
Study: 32584174

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (10 mg/site)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bupivacaine HCl (10 mg/site)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bupivacaine HCl
Number of subjects: 6
Study: 35688444

Group type: EXPERIMENTAL
Intervention: Hyperosmolar saline (593 mOsm/L)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isotonic lactated Ringer's (273 mOsm/L)
Number of subjects: 46
Study: 34633280

Group type: EXPERIMENTAL
Intervention: Unitisation intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 45
Study: 33075100

Group type: EXPERIMENTAL
Intervention: Fitbit intervention
Number of subjects: 29
Study: 34112721

Group type: EXPERIMENTAL
Intervention: OxyGenie control (SLE6000 ventilator)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CLiO2 control (AVEA ventilator)
Number of subjects: 15
Study: 32046652

Group type: EXPERIMENTAL
Intervention: General practitioners (GPs)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Nursing home (NH) staff
Number of subjects: 1121
Study: 36130170

Group type: EXPERIMENTAL
Intervention: 3-month culturally tailored Facebook group intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Referral resources on evidence-based cessation treatments (control)
Number of subjects: 60
Study: 33676997

Group type: EXPERIMENTAL
Intervention: Reconnection to mechanical ventilation (MV) for 1 hour after successful spontaneous breathing trial (SBT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Direct extubation (DE)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Reconnection to MV for 1 hour after SBT (among patients ventilated for more than 72 hours)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Direct extubation (DE) (among patients ventilated for more than 72 hours)
Number of subjects: 336
Study: 33185670

Group type: COMPARATOR
Intervention: Evolocumab, 140 mg every 2 weeks or 420 mg monthly
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Simvastatin, 40 mg daily for 30 days followed by 80 mg daily thereafter
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Ezetimibe, 10 mg daily plus simvastatin, 40 mg daily
Number of subjects: 3187
Study: 35962423

Group type: EXPERIMENTAL
Intervention: Behavioral Anger Response Questionnaire for Children (BARQC-V)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Maladaptive anger coping styles (Rumination and Direct Anger-out)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Adaptive anger coping style (Assertion)
Number of subjects: 1084
Study: 34110701

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (CHO) - 300 ml water containing 75 g glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (CHO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON) - placebo
Number of subjects: 8
Study: 33407507

Group type: EXPERIMENTAL
Intervention: KCG metrics computed on 50 Hz SCG/BCG signals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: KCG metrics computed on 1 kHz SCG/BCG signals
Number of subjects: 12
Study: 32331899

Group type: EXPERIMENTAL
Intervention: TMR conversion at 8 weeks (T8)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TMR conversion at 10 weeks (T10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TMR conversion at 12 weeks (T12)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TMR conversion (any group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Component-fed diet (Control)
Number of subjects: 40
Study: 33248754

Group type: EXPERIMENTAL
Intervention: Boosted regression tree (BRT) models incorporating climate environment variables
Number of subjects: 13431

Group type: EXPERIMENTAL
Intervention: Full-variable model
Number of subjects: 13431
Study: 33715526

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg‐1 BM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.3 g.kg‐1 BM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 35405112

Group type: EXPERIMENTAL
Intervention: Transition bundle
Number of subjects: 604

Group type: COMPARATOR
Intervention: Care coordinator
Number of subjects: 604
Study: 33548647

Group type: EXPERIMENTAL
Intervention: Bagging-based ensemble neural networks (BGNN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN) and decision tree (DT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning models (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shapley additive explanation (SHAP) method
Number of subjects: 0
Study: 32841751

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using methylene blue followed by IPL illumination
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Candida antigen immunotherapy using 0.1 ml of candida albicans antigen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group receiving 0.1 ml saline
Number of subjects: 39
Study: 32826830

Group type: EXPERIMENTAL
Intervention: Self-Selected Rest Interval (SSRI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fixed Rest Interval (FRI)
Number of subjects: 33
Study: 32007170

Group type: EXPERIMENTAL
Intervention: Deep learning biomarker for cancer-specific survival
Number of subjects: 1842
Study: 32845808

Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting sinus stents
Number of subjects: 181

Group type: COMPARATOR
Intervention: Nasopore packs
Number of subjects: 181
Study: 34114771

Group type: EXPERIMENTAL
Intervention: Seeds consumption (specifically pumpkin seeds)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Flaxseed preference
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Sunflower preference
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Increasing frequency of seeds consumption
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Pumpkin seeds consumption
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Overall seeds consumption
Number of subjects: 889
Study: 35753969

Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training (PFMT)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 362
Study: 33691158

Group type: EXPERIMENTAL
Intervention: Di(2‐ethylhexyl) phthalate (DEHP) exposure
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Di-iso-butyl phthalate (DiBP) and benzyl butyl phthalate (BzBP) exposure
Number of subjects: 436
Study: 35866596

Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia (MIH) exposure (FiO2: 15%, 3×2 h per day for seven consecutive days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia (MIH) exposure
Number of subjects: 5
Study: 34842202

Group type: EXPERIMENTAL
Intervention: Systematic early identification of work-related stress (WRS) by a validated instrument, GP awareness supported by a brief training session, patients' self-reflection by instrument completion, GP giving feedback, GP identifying preventive measures
Number of subjects: 271

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 271
Study: 35444577

Group type: EXPERIMENTAL
Intervention: Social Cognition Individualized Activities Lab (SoCIAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 33190032

Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33568346

Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin (GC), given every 21 days for four cycles
Number of subjects: 237

Group type: COMPARATOR
Intervention: dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC), given every 14 days for four cycles
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: COXEN GEM score for GC in GC-treated patients
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: COXEN GEM score for ddMVAC in ddMVAC-treated patients
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Pooled arms (GC and ddMVAC) using GC GEM score
Number of subjects: 237
Study: 32564051

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrashort wave (UW)
Number of subjects: 80
Study: 35589358

Group type: EXPERIMENTAL
Intervention: Simulation preparedness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33079133

Group type: EXPERIMENTAL
Intervention: Genetic upregulation of IL-6 signaling
Number of subjects: 500199

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 500199

Group type: COMPARATOR
Intervention: CRP levels
Number of subjects: 500199
Study: 32593918

Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (14 days after surgery)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Late rehabilitation group (14 weeks after surgery)
Number of subjects: 235
Study: 36099420

Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 499

Group type: COMPARATOR
Intervention: Education-only condition
Number of subjects: 499

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Theory-based intervention (for individuals with low pre-intervention risk perceptions)
Number of subjects: 499
Study: 34352729

Group type: EXPERIMENTAL
Intervention: Eccentric contraction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eccentric contraction at 20° position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concentric contraction
Number of subjects: 20
Study: 34957976

Group type: EXPERIMENTAL
Intervention: Full dose PTX (400 mg TID)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduced dose PTX (200 mg TID)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no PTX)
Number of subjects: 40
Study: 35538448

Group type: EXPERIMENTAL
Intervention: Swaddle and sucrose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swaddle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (routine blood sampling)
Number of subjects: 60
Study: 35636061

Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT) once a week
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation program (CRP)
Number of subjects: 15
Study: 34161602

Group type: COMPARATOR
Intervention: Exercise plus diet
Number of subjects: 351

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 351

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 351
Study: 33378403

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Hybrid therapy (esomeprazole 40 mg and amoxicillin 1 g twice daily for 14 days, adding metronidazole 500 mg and clarithromycin 500 mg twice daily in the last 7 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Hybrid therapy
Number of subjects: 140
Study: 35147968

Group type: EXPERIMENTAL
Intervention: Fronto‐orbital band anterior displacement during operation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no anterior displacement)
Number of subjects: 31
Study: 32157524

Group type: EXPERIMENTAL
Intervention: Primary site surgery
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Chemo/targeted therapy
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Non-Hispanic Black versus White patients
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Visceral versus bone-only metastases
Number of subjects: 3231

Group type: COMPARATOR
Intervention: Lowest versus highest income quartile
Number of subjects: 3231
Study: 35447085

Group type: EXPERIMENTAL
Intervention: SCB-2019 (two doses, 21 days apart)
Number of subjects: 30174

Group type: EXPERIMENTAL
Intervention: SCB-2019 (one dose)
Number of subjects: 30174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30174

Group type: EXPERIMENTAL
Intervention: Previous exposure to SARS-CoV-2
Number of subjects: 30174
Study: 34024504

Group type: EXPERIMENTAL
Intervention: Dietary counselling and daily oral nutritional supplement (ONS) containing 33.8 g of protein, 2.2 g EPA, and 1.1 g DHA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care including dietary counselling and protein supplementation when needed
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dietary counselling and intended protein/fish-oil supplementation
Number of subjects: 30
Study: 32585223

Group type: EXPERIMENTAL
Intervention: Local anesthesia (4 intracervical injections of bupivacaine hydrochloride 0.5%)
Number of subjects: 208

Group type: COMPARATOR
Intervention: General anesthesia (fentanyl, propofol, laryngeal mask with sevoflurane maintenance)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 208

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 208